The small-profile device expands to capture clots like large-bore systems while offering good reduction in RV/LV ratio at 48 ...

Follow-up over 10 years may show different patterns, and experts predict DCBs will likely be useful in certain populations.

The NyokAssist device, from China, had few adverse outcomes by 30 days. More devices—and more trials—are on the way.

The single-arm INVEST-CTO study showed high procedural success with a two-part intervention, but questions remain.

Experts gathered at the TCT MedTech Innovation Forum to discuss successes, failures, barriers, and solutions in healthcare.

Patrick O’Gara speaks with Sean Pinney about the evaluation and treatment of patients with severe tricuspid regurgitation.

Mamas Mamas and Evald Christiansen discuss the 10-year data comparing DES PCI and CABG for LM disease.

A total of 399 patients underwent TEE and were taking their assigned treatment at 60 days follow-up.

One question, in light of FREEDOM, is how well new DES compare with CABG in patients with diabetes and multivessel disease.

Physicians will remain in the loop, but AI can “turbocharge and augment our abilities,” an emergency medicine physician says.

Changes are afoot to meet higher caseloads amid rising demand, the survey of 6,830 cardiovascular providers suggests.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...